An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

If you have metastatic non-small-cell lungcancer (NSCLC), you might wonder if the treatment plan that your doctor recommended is the best one for you. Metastatic NSCLC is “stage IV” or ...

Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...

An update from Abbisko Cayman Limited ( ($HK:2256) ) is now available. Abbisko Cayman Limited announced a cooperation agreement between its ...

Findings from a phase 2 trial published in JTO Clinical and Research Reports suggest that pembrolizumab (Keytruda) plus ...

The collaboration focuses on the development of the Lunit SCOPE Genotype Predictor, an AI-driven tool designed to rapidly and ...

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung ...

Nicolas Girard, MD, PhD, discusses the final overall survival results from the MARIPOSA trial of amivantamab plus lazertinib in EGFR-mutant advanced non–small cell lung cancer.